| |
| Issue |
Title |
| |
| No 10 (2025) |
Role of the immunotherapy in the treatment of biliary tract cancers: Review of current clinical trials and retrospective analysis |
Abstract
PDF (Rus)
|
|
E. V. Ledin, V. I. Stolyarov, E. O. Chuykova |
| |
| No 10 (2025) |
A case of long-term therapy of hepatocellular carcinoma with atezolizumab and bevacizumab combination |
Abstract
PDF (Rus)
|
|
K. V. Menshikov, A. V. Sultanbaev, Sh. H. Musin, V. A. Valishin, I. A. Men′shikova, V. S. Chalov, N. I. Sultanbaeva, Sh. N. Galimov |
| |
| No 10 (2025) |
Can the complete pathomorphological response be predicted based on PET/CT data in patients with resectable non-small cell lung cancer after neoadjuvant chemotherapy? |
Abstract
PDF (Rus)
|
|
E. S. Denisova, K. K. Laktionov, V. A. Kuzmina, M. S. Ardzinba, M. S. Ardzinba |
| |
| No 10 (2025) |
Efficacy of combination immunotherapy in patients with generalized uveal melanoma: real clinical practice |
Abstract
PDF (Rus)
|
|
A. V. Sultanbaev, I. A. Tuzankina, A. F. Nasretdinov, N. I. Sultanbaeva, K. V. Menshikov, Sh. I. Musin, V. M. Zabelin, R. T. Ayupov, V. E. Askarov, R. R. Rakhimov, A. A. Izmailov, D. A. Kudlay |
| |
| No 10 (2024) |
Predictors of the immunochemotherapy effectiveness of atezolizumab in combination with etoposide and carboplatin in patients with advanced small cell lung cancer |
Abstract
PDF (Rus)
|
|
A. E. Kuzminov, T. D. Barbolina, E. V. Reutova, D. I. Yudin, V. V. Breder, K. K. Laktionov |
| |
| No 10 (2024) |
Long-term outcomes of durvalumab after chemoradiotherapy in locally advanced non-small cell lung cancer in Russia |
Abstract
PDF (Rus)
|
|
D. I. Yudin, К. К. Laktionov, F. V. Moiseenko, D. M. Ponomarenko, M. V. Сhernykh, V. A. Chubenko, N. V. Levchenko, V. V. Kozlov, E. О. Stepanova, M. N. Khagazheeva, D. Yu. Yukalchuk |
| |
| No 10 (2024) |
Approaches to the treatment of oligometastatic melanoma in the era of immunotargeted therapy |
Abstract
PDF (Rus)
|
|
E. V. Ledin, V. I. Stolyarov |
| |
| No 22 (2023) |
Immunotherapeutic options for management of metastatic cervical cancer |
Abstract
PDF (Rus)
|
|
K. V. Menshikov, A. V. Sultanbaev, Sh. I. Musin, I. A. Menshikovа, N. I. Sultanbaeva, A. V. Chashchin, D. О. Lipatov, A. A. Izmailov |
| |
| No 22 (2023) |
Efficacy of immunotherapy in patients with non-small cell lung cancer |
Abstract
PDF (Rus)
|
|
M. A. Lyadova, E. A. Denisova, D. S. Fedorinov, Yu. S. Esakov, A. S. Orlova, D. A. Vozniuk, K. V. Lyadov, V. N. Galkin |
| |
| No 22 (2023) |
Advisory board resolution: The role of the adjuvant atezolizumab plus bevacizumab in patients with hepatocellular carcinoma at high risk of recurrence following surgical resection or ablation |
Abstract
PDF (Rus)
|
|
V. V. Breder, I. A. Pokataev, V. V. Petkau, M. Yu. Fedyanin, E. V. Ledin, V. E. Zagainov, S. V. Shapoval, D. A. Granov, P. V. Balakhnin, N. E. Kudashkin, I. V. Pogrebnyakov, N. V. Popova, E. A. Moroz |
| |
| No 22 (2023) |
Combination of atezolizumab and bevacizumab in patients with inoperable hepatocellular cancer in real clinical practice |
Abstract
PDF (Rus)
|
|
V. V. Petkau, D. Yu. Shemetov, K. O. Semenova, V. A. Chubenko, A. V. Sultanbaev, K. V. Menshikov, O. Yu. Novikova, R. V. Orlova, N. V. Popova, A. S. Antipin, M. R. Mukhitova, A. A. Tarkhanov, K. E. Kiseleva |
| |
| No 22 (2022) |
First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia |
Abstract
PDF (Rus)
|
|
D. I. Yudin, K. K. Laktionov, F. V. Moiseenko, D. M. Ponomarenko, E. A. Chekh, V. A. Chubenko, N. V. Levchenko, V. V. Kozlov, E. О. Stepanova, K. A. Sarantseva, E. S. Denisova, M. S. Ardzinba, D. Yu. Yukalchuk |
| |
| 1 - 12 of 12 Items |
|
